Women who are pregnant or wishing to become pregnant during the study period, women who are breastfeeding, subjects with immune system deficiency (HIV or who are performing or performed in the last 90 days treatments such as chemotherapy, radiation therapy, high doses of corticosteroids (greater than 20 mg / day for more than 14 days) or immunosuppressants), receptors of immunoglobulins or blood products in the last 180 days, people with decompensated autoimmune diseases, such as systemic lupus erythematosus, sclerosis multiple, Guillain-Barré syndrome, myasthenia gravis, scleroderma, have received an attenuated vaccine in the last 30 days or inactivated in the last 15 days, fever greater than 37.8 degrees Celsius and / or inflammatory / infectious oropharyngeal process, previous history of positive test for SARS-CoV-2 by PCR or Rapid Test or serology, Covid-19 suspected clinical history and / or physical examination, such as fever (greater than 38 degrees Celsius), odynophagia, cough, dyspnoea and anosmia, anaphylactic-type hypersensitivity to any component of the vaccine, any other clinical condition that, at the discretion of the investigator, may interfere with the results of the study or may bring some risk to the study volunteer, it's be participating or wish to participate in another study that is evaluating the use of another vaccine.

Women who are pregnant or wishing to become pregnant during the study period, women who are breastfeeding, subjects with immune system deficiency (HIV or who are performing or performed in the last 90 days treatments such as chemotherapy, radiation therapy, high doses of corticosteroids (greater than 20 mg / day for more than 14 days) or immunosuppressants), receptors of immunoglobulins or blood products in the last 180 days, people with decompensated autoimmune diseases, such as systemic lupus erythematosus, sclerosis multiple, Guillain-Barré syndrome, myasthenia gravis, scleroderma, have received an attenuated vaccine in the last 30 days or inactivated in the last 15 days, fever greater than 37.8 degrees Celsius and / or inflammatory / infectious oropharyngeal process, previous history of positive test for SARS-CoV-2 by PCR or Rapid Test or serology, Covid-19 suspected clinical history and / or physical examination, such as fever (greater than 38 degrees Celsius), odynophagia, cough, dyspnoea and anosmia, anaphylactic-type hypersensitivity to any component of the vaccine, any other clinical condition that, at the discretion of the investigator, may interfere with the results of the study or may bring some risk to the study volunteer, it's be participating or wish to participate in another study that is evaluating the use of another vaccine.